Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
Feiyue Zheng, Yi Zhang, Shuang Chen, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 123, pp. 109661-109661
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation
Yifat Geffen, Shankara Anand, Yo Akiyama, et al.
Cell (2023) Vol. 186, Iss. 18, pp. 3945-3967.e26
Open Access | Times Cited: 75
Cyclin-dependent kinases in DNA damage response
Mateusz Kciuk, Adrianna Gielecińska, Somdutt Mujwar, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 3, pp. 188716-188716
Open Access | Times Cited: 73
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
Antonella Padella, Andrea Ghelli Luserna di Rorà, Giovanni Marconi, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 71
Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications
Rachel Shi, Chengheng Liao, Qing Zhang
Cells (2021) Vol. 10, Iss. 3, pp. 678-678
Open Access | Times Cited: 96
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy
Lukáš Górecki, Martin Andrš, Martina Řezáčová, et al.
Pharmacology & Therapeutics (2020) Vol. 210, pp. 107518-107518
Closed Access | Times Cited: 86
Recent advances of benzimidazole as anticancer agents
Sneha Venugopal, Balwinder Kaur, Anil Verma, et al.
Chemical Biology & Drug Design (2023) Vol. 102, Iss. 2, pp. 357-376
Closed Access | Times Cited: 29
Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship
Pronoy Kanti Das, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, et al.
European Journal of Medicinal Chemistry (2024) Vol. 274, pp. 116535-116535
Closed Access | Times Cited: 12
Regulation and pharmacological targeting of RAD51 in cancer
McKenzie K. Grundy, Ronald J. Buckanovich, Kara A. Bernstein
NAR Cancer (2020) Vol. 2, Iss. 3
Open Access | Times Cited: 58
The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review
Chien-Hui Lau, Kok‐Min Seow, Kuo-Hu Chen
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8125-8125
Open Access | Times Cited: 35
Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
Qinglei Gao, Jianqing Zhu, Weidong Zhao, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 11, pp. 2278-2285
Open Access | Times Cited: 29
Recent advances in PLGA-based nanofibers as anticancer drug delivery systems
Malihe Sadat Razavi, Alyeh Abdollahi, Atefeh Malek-Khatabi, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 85, pp. 104587-104587
Closed Access | Times Cited: 21
Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma
Naoka Tamura, Nadeem Shaikh, Daniel Muliaditan, et al.
Cancer Research (2020) Vol. 80, Iss. 22, pp. 4946-4959
Open Access | Times Cited: 42
Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy
A. MacPherson, Simon C. Barry, Carmela Ricciardelli, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 9, pp. 2967-2967
Open Access | Times Cited: 41
Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
Sandra van Wilpe, Sofie H. Tolmeijer, Rutger H.T. Koornstra, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2249-2249
Open Access | Times Cited: 39
CDCA8, targeted by MYBL2, promotes malignant progression and olaparib insensitivity in ovarian cancer.
Gonghua Qi, Chenyi Zhang, Hanlin Ma, et al.
(2021) Vol. 11, Iss. 2, pp. 389-415
Closed Access | Times Cited: 37
DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
María Ovejero-Sánchez, Rogelio González‐Sarmiento, Ana B. Herrero
Cancers (2023) Vol. 15, Iss. 2, pp. 448-448
Open Access | Times Cited: 15
DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome
Kristýna Tomášová, Andrea Čumová, Karolína Šeborová, et al.
Cancers (2020) Vol. 12, Iss. 7, pp. 1713-1713
Open Access | Times Cited: 33
Bioinformatics: From NGS Data to Biological Complexity in Variant Detection and Oncological Clinical Practice
Serena Dotolo, Riziero Esposito Abate, Cristin Roma, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2074-2074
Open Access | Times Cited: 22
Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety
Myongjae Lee, In‐Gyu Je, Jeong Eun Kim, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 3, pp. 333-342
Open Access | Times Cited: 11
Overcoming PARP inhibitor resistance in ovarian cancer
Pamela Soberanis Pina, Stéphanie Lheureux
International Journal of Gynecological Cancer (2023) Vol. 33, Iss. 3, pp. 364-376
Closed Access | Times Cited: 11
Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer
Trudy Janice Philips, Britt Erickson, Stefani N. Thomas
Frontiers in Oncology (2025) Vol. 14
Open Access
Poly(ADP-ribose) polymerase inhibitors in cancer therapy
Zi-Qi Zhu, Yujun Shi
Chinese Medical Journal (2025)
Open Access
PARP14 inhibits microglial activation via NNT to alleviate depressive-like behaviors in mice
Xiaoyu Yu, Tingting Yang, Di Wu, et al.
Brain Behavior and Immunity (2025) Vol. 126, pp. 235-246
Closed Access
Retrospective Analysis of BRCA -Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors
M.B. Rao, Madeline Merrill, Mary Troxel, et al.
JCO Precision Oncology (2025), Iss. 9
Closed Access
RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
Lise M. van Wijk, Andreea B. Nilas, Harry Vrieling, et al.
Expert Review of Molecular Diagnostics (2021) Vol. 22, Iss. 2, pp. 185-199
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top